The phosphoinositide 3-kinase (PI3K)-AKT signaling pathway is a key regulator of cell growth, survival, and metabolism and is frequently altered in estrogen receptor–positive (ER+) breast cancer. Approximately 30 to 40 percent of advanced ER+ breast cancers have gain of function mutations in PIK3CA, while 5...

Treatment with a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, such as abemaciclib, plus (+) endocrine therapy (ET) has been shown to improve survival in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, compared to ET alone. Previous research...

In preinvasive and invasive breast cancer, breast-conserving surgery (BCS) has demonstrated similar survival outcomes to mastectomy, in addition to improvements in outcomes such as health-related quality of life and patient satisfaction. Chest wall perforator flap (CWPF) reconstruction can be utilized for volume replacement in oncoplastic...

Preoperative window-of-opportunity studies can provide key information on molecular drug response, pharmacodynamic (PD) effects, and downstream effects of medications, such as endocrine therapy (ET), in early breast cancer, as well as potentially predicting impact in advanced breast cancer. Data from the Phase I EMBER trial...

Endocrine therapy (ET) is the standard of care for patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC), but efficacy and patient experiences can be improved upon. Preclinical data has shown that the next-generation oral selective estrogen receptor degrader (SERD) imlunestrant has favorable pharmacokinetic (PK)...